We use cookies to ensure that our site works correctly and provides you with the best experience. If you continue using our site without changing your browser settings, we'll assume that you agree to our use of cookies. Find out more about the cookies we use and how to manage them by reading our cookies policy. Hide

Julia Levy Award

Julia Levy Award

Established 2006

The Julia Levy Award is presented to an individual to recognize successful commercialization of innovation in Canada, specifically in the field of Bio-medical Science and Engineering.

Eligibility: The Julia Levy Award recognizes successful commercialization of bio-medical innovation in Canada, with a particular focus, where relevant, on the synergistic relationship between university and business. New product development requires not only leading edge innovation but active management of the commercialization step/s. This award has been established to encourage innovators to give the commercialization step sufficient attention.

Membership of SCI is not a prerequisite for receiving this award.

Description of Award: A plaque

Presented at: The award shall normally be presented at the annual SCI Canada Awards Dinner, typically held in early April, where the winner will be expected to attend and deliver a short acceptance speech. The winner may be invited to present a lecture at this event.

Frequency: Annual

Nomination Deadline: 30 September

Sponsor: SCI Canada

The 2017 winner of the Julia Levy Award is:

David Allan
Cresswell Advisors Inc.

David Allan is the Principal at Cresswell Advisors Inc. He was the founding and sunset chair of YM BioSciences Inc., and CEO from 1998-2011; founding chair of Formation Biologics; executive chair of Stem Cell Therapeutics (now Trillium Therapeutics). He has been a member of the awards selection committee of Canada’s Networks of Centres of Excellence and the multidisciplinary assessment committee of the Canada Foundation for Innovation. He was formerly a governor of the Toronto Stock Exchange and, 1992, founded the first biotech-specific investment banking team in Canada.

He is the recipient of the 2016 Life Sciences Ontario Leadership Award and the 2012 Gold Leaf Award from BIOTECanada.

In the final decade of a 35-year career in investment banking he founded the first Canadian investment banking and research team specializing in the life sciences.

Mr. Allan is also a founding and sunset chair of the Toronto Stock Exchange Market Access Implementation Committee that created access for small and medium-sized enterprises to Canada’s principal capital market and was a member, and working group chair of the Ontario Biotechnology Advisory Board. He has been a board member of the Shaw Festival Theatre and of the board of trustees for the Ontario College of Art and Design.

Related Links

Share this article